View Article Online / Journal Homepage / Table of Contents for this issue

Total Synthesis of (+)- α -Homonojirimycin

Sakae Aoyagi, Satoshi Fujimaki and Chihiro Kibayashi*


Tokyo College of Pharmacy, Horinouchi, Hachioji, Tokyo, 192-03, Japan

The total synthesis of (+)- α -homonojirimycin, the first example of a naturally occurring azaheptose, was achieved in 13 steps utilizing the allylic alcohol **3** as a non-carbohydrate chiral building block.


 α -Homonojirimycin 1, recently isolated from leaves of *Omphalea diandra*,¹ is the first example of a naturally occurring azapyranose analogue of a heptose.² It is a powerful α -glucosidase inhibitor and is expected to be a drug candidate for antidiabetic therapy. Indeed, MDL 25637 2, a novel compound designed as a prototype transition-state analogue, has been shown to possess potent inhibitory activity towards α -glucosidases.^{3,4} Thus, in the course of preparing 2, 1 has

been obtained by chemical transformation of the natural azahexose nojirimycin.⁵ However, there has so far been no report of the total synthesis of 1.

Recent investigation from this laboratory has revealed that the chiral allylic alcohol **3** serves as a versatile, common chiral building block in the preparation of several naturally occurring azahexoses.⁶ In this communication we describe our efforts, which resulted in the enantioselective total synthesis




Scheme 1 Reagents: i, (+)-DET, Ti(OPri)₄, TBHP (ref. 5a); ii, Et₂AlNHCH₂Ph, CH₂Cl₂; iii, PhCH₂OCOCl, aq. Na₂CO₃, CH₂Cl₂; iv, CH₃OCH₂Cl, (Pri)₂NEt, CHCl₃, then (Buⁿ)₄NF, THF; v,(COCl)₂, Me₂SO, Et₃N, CH₂Cl₂; vi, Ph₃PCH₃Br, BuⁿLi, THF; vii, *N*-methylmorpholine oxide, OsO₄, aq. Me₂CO.



of (+)- α -homonojirimycin 1 via a non-carbohydrate based approach utilizing 3.

The allylic alcohol **3** was converted to the *syn* epoxide **4** by the Sharpless asymmetric epoxidation *via* the procedure previously reported.^{6a} Regio- and stereo-selective ring open-



Scheme 2 Reagents: i, $Me_2Bu^{t}SiCl$, imidazole, DMF, then MsCl, Et_3N , CH_2Cl_2 ; ii, H_2 , $Pd(OH)_2$, MeOH; iii, Et_3N , MeOH, reflux; iv, conc. HCl, MeOH, reflux.

ing of the epoxide was effected by using dialkylaluminium amide according to Overman's method.7 Treatment of 4 with 1 equiv. of Et₂AlNHCH₂Ph in CH₂Cl₂ at 0 °C resulted in the amino-alcohol 5[†] as a single diastereoisomer in 70% yield (Scheme 1). The amino group of 5 was selectively protected with benzyl chloroformate (aq. Na₂CO₃, CH₂Cl₂) to afford the carbamate 6 (98% yield), which was then converted to 7 by methoxymethylation [2 equiv. of MOMCl and (Pri)2NEt] followed by removal of the silvl group [(Buⁿ)₄NF, THF] in 86% overall yield from 5. Swern oxidation [(COCl)₂, Me₂SO, Et_3N of 7 gave the aldehyde 8 (98% yield), which was transformed into the alkene 9 (84%) by the Wittig reaction (Ph₃PCH₃Br, BuⁿLi, THF). Hydroxylation of 9 using a catalytic quantity of osmium tetroxide with 2 equiv. of N-methylmorpholine oxide in aqueous acetone resulted in 2.5: 1 diastereoselectivity in favour of the desired anti-product 10 (total yield of 10 and 11: 90%). The observed anti preference for 10 can be rationalized by the transition-state conformation (Fig. 1) with the dioxolane alkyl group anti and the dioxolane oxygen inside. Addition of osmium to the alkene, thus, proceeds in accord with the inside alkoxy concept,8 in which the electrophile adds anti to the alkyl group and inside to the alkoxy group in order to maximize σ_{C-C}/π overlap and minimize σ^*_{C-O}/π overlap.

Compound 10 was converted to 12 via selective silylation of the primary alcohol function with t-butyldimethylsilyl chloride (imidazole, DMF), followed by mesylation under the standard conditions in 77% overall yield (Scheme 2). De-*N*-protection

[†] All new compounds gave spectral data (IR, ¹H and ¹³C NMR, and mass spectra) in accord with the assigned structure, and satisfactory combustion analysis or accurate mass measurement. *Selected data*: **5**: $[\alpha]_D^{26} + 10.6^{\circ}$ (*c* 0.8, CHCl₃). **6**: $[\alpha]_D^{27} - 33.0^{\circ}$ (*c* 0.8, CHCl₃). **7**: $[\alpha]_D^{29} - 19.4^{\circ}$ (*c* 0.1, CHCl₃). **8**: $[\alpha]_D^{26} - 13.0^{\circ}$ (*c* 0.3, CHCl₃). **1**: $[\alpha]_D^{27} - 19.0^{\circ}$ (*c* 1.1, CHCl₃). **10**: $[\alpha]_D^{26} - 17.1^{\circ}$ (*c* 0.3, CHCl₃). **11**: $[\alpha]_D^{25} - 27.8^{\circ}$ (*c* 0.9, CHCl₃). **12**: $[\alpha]_D^{26} - 20.0^{\circ}$ (*c* 0.3, CHCl₃). **14**: $[\alpha]_D^{25} + 107.0^{\circ}$ (*c* 0.6, CHCl₃). **1**: ¹H NMR (400 MHz, D₂O) δ (D₂O) 2.80 (1 H, dd, J 9.5, 7.2, 2.9 Hz), 3.15 (1 H, dd, J 9.5, 9.4 Hz), 3.23 (1 H, dd, J 9.2, 6.2, 5.1 Hz), 3.44 (1 H, dd, J 9.5, 9.4 Hz), 3.52 (1 H, dd, J 11.4, 5.2 Hz), 3.69 (1 H, dd, J 9.5, 6.1 Hz), 3.74 (1 H, dd, J 10.5, 5.1 Hz), 3.77 (1 H, dd, J 10.5, 9.2 Hz), 3.85 (1 H, dd, J 11.4, 2.9 Hz); ¹³C NMR (100.6 MHz, D₂O) δ (dioxane, δ 67.40) 54.89 (CH), 57.23 (CH₂), 57.69 (CH), 69.92 (CH₂), 72.43 (CH), 72.96 (CH), 75.19 (CH).

of 12 was carried out *via* hydrogenolysis over palladium hydroxide in methanol. At the conclusion of the reaction the catalyst was removed by filtration, and triethylamine was added to the filtrate containing 13. The resulting mixture was refluxed to afford the cyclization product 14 in 81% yield from 12. Finally, 14 was deprotected by treatment with HCl–MeOH at reflux. Application to an ion-exchange column (Dowex 1-X8) followed by lyophilization provided pure (+)- α -homonojirimycin 1 in 68% yield. Synthetic 1 had m.p. 205–207 °C (decomp.) and $[\alpha]_D^{27} + 82.7^\circ$ (*c* 0.8, H₂O) identical with those published for the natural product [m.p. 206–207 °C and $[\alpha]_D^{20}$ +88.2° (*c* 0.54, H₂O)]⁵ and showed spectra (¹H and ¹³C NMR) identical with the corresponding authentic spectra of 1.

The synthetic approach for the azaheptose presented here demonstrates synthetic versatility of the allylic alcohol **3** as a common chiral building block for the preparation of azapyranoses having inhibitory activity toward glycosidases.

We are grateful to Dr P. S. Liu of Merrell Dow Research Institute, for the ¹H and ¹³C NMR spectra of α -homonojirimycin.

Received, 6th July 1990; Com. 0/03056B

References

- 1 G. C. Kite, L. E. Fellows, G. W. J. Fleet, P. S. Liu, A. M. Scofield and N. G. Smith, *Tetrahedron Lett.*, 1988, **29**, 6483.
- 2 For synthesis and enzyme inhibitory characteristics of α-homonojirimycin analogues, see: G. W. J. Fleet, S. K. Namgoong, C. Barker, S. Baines, G. S. Jacob and B. Winchester, *Tetrahedron Lett.*, 1989, **30**, 4439; I. Bruce, G. W. J. Fleet, I. C. di Bello and B. Winchester, *Tetrahedron Lett.*, 1989, **30**, 7257; B. Winchester, C. Barker, S. Baines, G. S. Jacob, S. K. Namgoong and G. Fleet, *Biochem. J.*, 1990, **265**, 277.
- 3 B. L. Rhinehart, K. M. Robinson, P. S. Liu, A. J. Payne, M. E. Wheatley and S. R. Wagner, J. Pharmacol. Exp. Ther., 1987, 241, 915.
- 4 P. S. Liu, J. Org. Chem., 1987, 52, 4717.
- 5 P. B. Anzeveno, L. J. Creemer, J. K. Daniel, C.-H. R. King and P. S. Liu, J. Org. Chem., 1989, 54, 2539.
- 6 (a) H. Iida, N. Yamazaki and C. Kibayashi, J. Org. Chem., 1987,
 52, 3337; (b) S. Aoyagi, S. Fujimaki, N. Yamazaki and C. Kibayashi, *Heterocycles*, 1990, 30, 783.
- 7 L. E. Overman and L. A. Flippin, Tetrahedron Lett., 1981, 22, 195.
- 8 (a) K. N. Houk, S. R. Moses, Y.-D. Wu, N. G. Rondon, V. Jäger, R. Schohe and F. R. Fronczek, J. Am. Chem. Soc., 1984, 106, 3880;
 (b) K. N. Houk, H.-Y. Duh, Y.-D. Wu and S. R. Moses, J. Am. Chem. Soc., 1986, 108, 2754.

1459